JorgeJ.NievaMD

Oncology • Los Angeles, CA

Head & Neck Cancer, Hematologic Oncology, Thoracic Cancer

Associate Professor, Medicine, Keck School of Medicine of the University of So California

Join to view full profile

Dr. Nieva is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Nieva's full profile

Already have an account?

Office
1441 Eastlake Ave
# NOR8302E
Los Angeles, CA 90089
Phone+1 323-865-3105

Fax+1 323-865-0061

Summary

Dr. Jorge Nieva is an oncologist in Los Angeles, CA and is affiliated with multiple hospitals in the area, including Los Angeles General Medical Center, Keck Hospital of USC, and USC Norris Comprehensive Cancer Center. He received his medical degree from University of California, Irvine, School of Medicine and has been in practice 24 years. He also speaks multiple languages, including Spanish. He specializes in head & neck cancer, hematologic oncology, and thoracic cancer and is experienced in amyloidosis, mesothelioma, hematologic oncology, lung cancer, and myelodysplasia. He has more than 100 publications and over 500 citings.

Education & Training

Scripps Clinic/Scripps Green HospitalFellowship, Hematology and Medical Oncology, 2000 - 2003
University of California (San Diego) Medical CenterResidency, Internal Medicine, 1997 - 2000
University of California, Irvine, School of MedicineClass of 1997

Certifications & Licensure

CA State Medical License 1999 - 2026
MT State Medical License 2007 - 2016
WY State Medical License 2007 - 2014
American Board of Internal Medicine Internal Medicine
American Board of Internal Medicine Hematology
American Board of Internal Medicine Medical Oncology

Clinical Trials

Lung-MAP: Biomarker-Targeted Second-Line Therapy in Treating Patients With Recurrent Stage IV Squamous Cell Lung Cancer Start of enrollment: 2014 Jul 08
Completed
Recombinant EphB4-HSA Fusion Protein and Pembrolizumab, MK-3475 Start of enrollment: 2017 Mar 10
Active, not recruiting
Phase 2
Pembrolizumab With or Without Anetumab Ravtansine in Treating Patients With Mesothelin-Positive Pleural Mesothelioma Start of enrollment: 2018 Oct 04
Active, not recruiting
Phase 1, Phase 2
Randomized Trial of Topotecan With M6620, an ATR Kinase Inhibitor, in Small Cell Lung Cancers and Small Cell Cancers Outside of the Lungs Start of enrollment: 2019 Dec 30
Active, not recruiting
Phase 2
Movement and Fitness Trackers in Determining Performance Status Start of enrollment: 2019 Mar 27
Recruiting
Not Applicable
Fluid Biopsy for the Diagnosis of Lung Cancer Start of enrollment: 2020 Jan 13
Recruiting
Subcutaneous Atezolizumab for the Treatment of Non-small Cell Lung Cancer Start of enrollment: 2022 Dec 07
Recruiting
Phase 2
Roles: Contact, Principal Investigator
Pembrolizumab in Treating Participants With Leukoplakia Start of enrollment: 2019 May 03
Recruiting
Phase 2
Roles: Contact, Principal Investigator
Epidemiology of Young Lung Cancer - Survey Start of enrollment: 2021 Feb 01
Recruiting
Roles: Contact
Join now to see all

Publications & Presentations

PubMed

Real-World Incidence of Anaplastic Lymphoma Kinase alterations in Hispanics with Non-Small Cell Lung Cancer at a Large Academic Institution in Los Angeles.
Darin Poei, Sana Ali, Jacob S Thomas, Jorge J Nieva, Robert C Hsu
Cancer Research Communications. 2025-01-14
Changing Treatment and Metastatic Disease Patterns in Patients with EGFR Mutated NSCLC: An Academic Thoracic Medical Investigator's Consortium Registry Analysis.
Margaret Stalker, Connor B Grady, Alex Watts, Wei-Ting Hwang, Krishna Chandrasekhara
JTO Clinical and Research Reports. 2025-01-01
Determining Line of Therapy from Real-World Data in Non-Small Cell Lung Cancer.
Connor B Grady, Wei-Ting Hwang, Joshua E Reuss, Wade Iams, Amanda Cass
Pharmacoepidemiology and Drug Safety. 2024-12-01

Press Mentions

Subcutaneous Cancer Immunotherapies Provide New Options for Physicians and PatientsDecember 12th, 2024
Rising Standards in Regulatory Decisions Highlight Challenges in Drug Development in Lung CancerFebruary 7th, 2023
FDA Committee Unanimously Rejects 131-I-Omburtamab for NeuroblastomaOctober 28th, 2022
Join now to see all

Professional Memberships

Other Languages

Spanish